ARIAD Announces Updated Data on AP26113 to Be Presented at the European Cancer Congress 2013 Meeting

Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

ARIAD Pharmaceuticals, Inc. (ARIA) today announced that updated data from its Phase 1/2 trial of AP26113, an investigational inhibitor of anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR) and c-ros oncogene 1 (ROS1), will be presented at the European Cancer Congress (the 38th ESMO, 32nd ESTRO, 17th ECCO) being held in Amsterdam, September 27 to October 1, 2013.

Updated results from the ongoing Phase 1/2 trial will be featured in an oral presentation on Saturday, September 28, 2013. The schedule and meeting location for the session, together with the abstract information, are listed below:

Oral Presentation at ECC 2013

Title:       Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies
Session: Lung Cancer Localized /Metastatic
Date & Time: Saturday, September 28, 11:15 a.m. (CEST)
Abstract No: 3.401
Presenter: D. Ross Camidge, M.D., Ph.D. (Colorado Cancer Center, Aurora, Colorado)
Location: Elicium 2

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

Contact:
ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com

View Comments